Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
Simpson, Eric L. (Oregon Health and Science University)
Silverberg, Jonathan (The George Washington University School of Medicine and Health Sciences)
Geng, Bob (University of California San Diego School of Medicine)
Carrascosa, José Manuel (Universitat Autònoma de Barcelona. Departament de Medicina)
Bieber, Thomas (University Hospital Zürich (Suïssa))
Brunner, Patrik M. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Staumont-Sallé, Delphine (University of Lille)
Ji, Chao (First Affiliated Hospital of Fujian Medical University)
Biswas, Pinaki (Pfizer Inc)
Feeney, Claire (Pfizer Ltd)
Hernández-Martín, Irene (Pfizer SLU Spain)
Rebollo Laserna, Francisco José (Pfizer SLU Spain)
Koppensteiner, Herwig (Pfizer Corp. Austria GmbH)

Data:	2025
Resum:	Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and DARE trials compared efficacy, safety, and quality of life following abrocitinib and dupilumab treatment in adults with moderate-to-severe AD, with or without comorbid asthma, allergic rhinitis, or food allergy. Data were pooled from patients who received abrocitinib (200 mg/day) or dupilumab (300 mg/every 2 weeks) for 16 weeks with concomitant topical therapy. Assessments by self-reported asthma, allergic rhinitis, or food allergy included the proportion of patients achieving Investigator's Global Assessment of clear or almost clear (IGA 0/1), ≥ 75% improvement in Eczema Area and Severity Index (EASI-75), ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4), least squares mean change from baseline in Dermatology Life Quality Index (DLQI) and SCORing Atopic Dermatitis (SCORAD), and safety. Of 1195 patients (abrocitinib, n = 588; dupilumab, n = 607), 377 (32%), 225 (19%), and 211 (18%) patients self-reported comorbid asthma, food allergy, or allergic rhinitis, respectively. Week 16 IGA 0/1 responses were comparable between patients with/without comorbidity with abrocitinib (52%/54% [with/without asthma], 50%/54% [with/without allergic rhinitis], and 53%/53% [with/without food allergy]) or dupilumab (42%/42%, 37%/43%, and 47%/41%). EASI-75 and PP-NRS4 responses and DLQI and SCORAD improvements were also comparable between patients with/without comorbidity in each treatment arm. Treatment-emergent adverse events were more common in patients with comorbidities in the abrocitinib (76%/67% [with/without asthma], 80%/67% [with/without allergic rhinitis], and 78%/67% [with/without food allergy]) and dupilumab (71%/53%, 71%/57%, and 62%/59%) arms. Abrocitinib and dupilumab improved AD signs and symptoms with a manageable safety profile in patients with moderate-to-severe AD, regardless of asthma, allergic rhinitis, or food allergy. Graphical Abstract available for this article.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Abrocitinib ; Allergic rhinitis ; Asthma ; Comorbidity ; Dupilumab ; Food allergy ; Moderate-to-severe atopic dermatitis ; Pruritus ; Quality of life
Publicat a:	Dermatology and Therapy, Vol. 15, Num. 11 (November 2025) , p. 3391-3407, ISSN 2190-9172

DOI: 10.1007/s13555-025-01516-w
PMID: 40987931

17 p, 3.2 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats